These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28522591)
1. Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors. Martin D; Fallaha S; Proctor M; Stevenson A; Perrin L; McMillan N; Gabrielli B Mol Cancer Ther; 2017 Sep; 16(9):1934-1941. PubMed ID: 28522591 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211 [TBL] [Abstract][Full Text] [Related]
3. Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers. Shaikh MH; Idris A; Johnson NW; Fallaha S; Clarke DTW; Martin D; Morgan IM; Gabrielli B; McMillan NAJ Oral Oncol; 2018 Nov; 86():105-112. PubMed ID: 30409290 [TBL] [Abstract][Full Text] [Related]
4. Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer. Gabrielli B; Bokhari F; Ranall MV; Oo ZY; Stevenson AJ; Wang W; Murrell M; Shaikh M; Fallaha S; Clarke D; Kelly M; Sedelies K; Christensen M; McKee S; Leggatt G; Leo P; Skalamera D; Soyer HP; Gonda TJ; McMillan NA Mol Cancer Ther; 2015 Dec; 14(12):2753-61. PubMed ID: 26516156 [TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146 [TBL] [Abstract][Full Text] [Related]
6. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo. Qi L; Zhang Y Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143 [TBL] [Abstract][Full Text] [Related]
7. Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237. Tayyar Y; Shiels R; Bulmer AC; Lam AK; Clarke D; Idris A; McMillan NA PLoS One; 2019; 14(11):e0225774. PubMed ID: 31774882 [TBL] [Abstract][Full Text] [Related]
9. MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas. Nair JS; Schwartz GK Oncotarget; 2016 Mar; 7(11):12893-903. PubMed ID: 26887042 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633 [TBL] [Abstract][Full Text] [Related]
12. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249 [TBL] [Abstract][Full Text] [Related]
13. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Marxer M; Ma HT; Man WY; Poon RY Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy. Iankov ID; Kurokawa CB; D'Assoro AB; Ingle JN; Domingo-Musibay E; Allen C; Crosby CM; Nair AA; Liu MC; Aderca I; Federspiel MJ; Galanis E Cancer Gene Ther; 2015 Sep; 22(9):438-44. PubMed ID: 26272026 [TBL] [Abstract][Full Text] [Related]
15. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750 [TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia. Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577 [TBL] [Abstract][Full Text] [Related]
17. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047 [TBL] [Abstract][Full Text] [Related]
18. Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition. Zhang Z; Zeng D; Zhang W; Chen A; Lei J; Liu F; Deng B; Zhuo J; He B; Yan M; Lei X; Wang S; Lam EW; Liu Q; Wang Z Cell Death Dis; 2021 Sep; 12(10):893. PubMed ID: 34593753 [TBL] [Abstract][Full Text] [Related]
19. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553 [No Abstract] [Full Text] [Related]
20. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]